MetaCap

Compass Therapeutics (CMPX) vs Cardiol Therapeutics (CRDL)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Cardiol Therapeutics (CRDL) has outperformed Compass Therapeutics (CMPX) over the past year, losing 11.3% versus a loss of 85.9%. Over five years, CRDL leads with a -60.1% price change compared with -78.6% for CMPX. Compass Therapeutics is the larger company by market cap ($123.9 million vs $110.1 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CMPX-85.87%CRDL-11.35%
+146%+24%-99%
Nov 21, 20251 yearNov 20, 2026
CMPX-80.22%CRDL-57.92%
+96%+4%-89%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CMPX versus CRDL key metrics
MetricCMPXCRDL
Share price$0.6882$0.8626
Market cap$123.94M$110.14M
1-day change+1.43%-2.28%
YTD return-87.18%-9.58%
1-year return-85.87%-11.35%
5-year return-78.63%-60.06%
EPS (TTM)$-0.46$-0.24
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$0—
Revenue growth (YoY)-100.00%—
Net income (latest FY)$-66.49M—
52-week high$6.88$2.34
52-week low$0.57$0.8417
Distance from 52-week high-90.00%-63.14%
Analyst consensusbuystrong_buy
Avg. price target upside+664.31%+874.96%
Average volume3.88M1.20M
Shares outstanding180.09M127.69M
Employees3918
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • CRDL has outperformed CMPX by 74.5 percentage points over the past year.

About Compass Therapeutics

CMPX stock →

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, develops antibody-based therapeutics for the treatment of various human diseases in the United States. The company's lead product candidate, tovecimig, is a bispecific antibody that targets delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A), which are critical to angiogenesis and tumor vascularization.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 39 employees

About Cardiol Therapeutics

CRDL stock →

Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 18 employees

CMPX vs CRDL FAQ

Which is bigger, Compass Therapeutics or Cardiol Therapeutics?

Compass Therapeutics (CMPX) is larger, with a market capitalization of $123.94M compared with $110.14M for Cardiol Therapeutics (CRDL).

Which stock has performed better over the past year, CMPX or CRDL?

CRDL returned -11.35% over the past 12 months, compared with -85.87% for CMPX (price return, excluding dividends). Past performance does not predict future results.

Are Compass Therapeutics and Cardiol Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons